Tulio de Oliveira mostly deals with Genetics, Demography, Acquired immunodeficiency syndrome, Virology and Genome. His Genetics study typically links adjacent topics like Genetic diversity. His Acquired immunodeficiency syndrome study combines topics in areas such as Transmission, Regimen, Logistic regression and Developing country.
His research in Virology intersects with topics in Antibody and Convalescent plasma, Coronavirus, Coronavirus disease 2019. His study in Genome is interdisciplinary in nature, drawing from both Genome-wide association study, Disease, Genetic association and Disease transmission. In his study, which falls under the umbrella issue of Young adult, Viral load is strongly linked to Cross-sectional study.
Virology, Drug resistance, Viral load, Transmission and Genetics are his primary areas of study. The study incorporates disciplines such as Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019 and Genotype in addition to Virology. His Drug resistance study integrates concerns from other disciplines, such as Regimen, Internal medicine, Cohort, HIV drug resistance and Efavirenz.
His Viral load study combines topics from a wide range of disciplines, such as Coinfection, Cross-sectional study and Intensive care medicine. In his papers, Tulio de Oliveira integrates diverse fields, such as Transmission and Demography. His research on Genome also deals with topics like
His main research concerns Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Virology, Pandemic and 2019-20 coronavirus outbreak. Tulio de Oliveira works mostly in the field of Coronavirus disease 2019, limiting it down to topics relating to Transmission and, in certain cases, Zika virus and Treatment outcome, as a part of the same area of interest. Tulio de Oliveira is studying Virus, which is a component of Virology.
Tulio de Oliveira has included themes like Epidemiology, Phylogenetics, Lineage, Outbreak and Whole genome sequencing in his Pandemic study. His research on Phylogenetics concerns the broader Genetics. His Outbreak research includes elements of Genotyping and Molecular epidemiology.
Tulio de Oliveira mainly focuses on Severe acute respiratory syndrome coronavirus 2, Pandemic, Coronavirus disease 2019, Coronavirus and Outbreak. Tulio de Oliveira combines subjects such as Environmental health, Regimen, Clinical endpoint, Randomized controlled trial and Adverse effect with his study of Severe acute respiratory syndrome coronavirus 2. His Pandemic research integrates issues from Epidemiology, Phylogenetics, Lineage, Whole genome sequencing and Genomics.
Tulio de Oliveira works mostly in the field of Epidemiology, limiting it down to topics relating to Molecular epidemiology and, in certain cases, Phylogenetic tree. The concepts of his Coronavirus disease 2019 study are interwoven with issues in Placebo, 2019-20 coronavirus outbreak, Incidence and Virology. Tulio de Oliveira interconnects Lineage, Antibody and Convalescent plasma in the investigation of issues within Virology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Detection of a SARS-CoV-2 variant of concern in South Africa.
Houriiyah Tegally;Eduan Wilkinson;Marta Giovanetti;Marta Giovanetti;Arash Iranzadeh.
Nature (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Constantinos Kurt Wibmer;Frances Ayres;Tandile Hermanus;Mashudu Madzivhandila.
Nature Medicine (2021)
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
Houriiyah Tegally;Eduan Wilkinson;Marta Giovanetti;Marta Giovanetti;Arash Iranzadeh.
medRxiv (2020)
An automated genotyping system for analysis of HIV-1 and other microbial sequences
Tulio De Oliveira;Koen Deforche;Sharon Cassol;Mika Salminen.
Bioinformatics (2005)
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Sandile Cele;Inbal Gazy;Inbal Gazy;Laurelle Jackson;Shi-Hsia Hwa.
Nature (2021)
New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.
Salim S Abdool Karim;Tulio de Oliveira.
The New England Journal of Medicine (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Vivek Shinde;Sutika Bhikha;Zaheer Hoosain;Moherndran Archary.
The New England Journal of Medicine (2021)
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis
Ravindra K Gupta;John Gregson;Neil Parkin;Hiwot Haile-Selassie.
Lancet Infectious Diseases (2017)
Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools.
Andrea Clemencia Pineda-Peña;Andrea Clemencia Pineda-Peña;Nuno Rodrigues Faria;Stijn Imbrechts;Pieter Libin.
Infection, Genetics and Evolution (2013)
Sixteen novel lineages of SARS-CoV-2 in South Africa.
Houriiyah Tegally;Eduan Wilkinson;Richard J. Lessells;Jennifer Giandhari.
Nature Medicine (2021)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Imperial College London
University College London
Rega Institute for Medical Research
Centre for the AIDS Programme of Research in South Africa
University of Cape Town
Stellenbosch University
National Health Laboratory Service
University of Oxford
University of the Witwatersrand
Heidelberg University
PSL University
Nielsen (United States)
University of North Carolina at Chapel Hill
Texas Instruments (United States)
University of Tartu
University of Saskatchewan
Tianjin University
Swansea University
University of Potsdam
University of Alberta
Colorado School of Mines
University of Bonn
University of Porto
University of Zurich
Tel Aviv University
Yale University